Kuvalanka Bolts Blueprint Medicines For COO Gig at Syros
Kyle Kuvalanka has been named the first chief operating officer of Cambridge, MA-based Syros Pharmaceuticals, a privately held startup developing so-called “gene control” drugs. Kuvalanka was previously the chief business officer of Blueprint Medicines (NASDAQ: BPMC), which went public and raised nearly $150 million in an IPO in April.
Underwriters and Partners
Xpertise: Watch + Learn
From Our Editors · Special Report
2019 Blockchain Outlook — Reality Check
Reality Check
Xconomy
Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed
From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Facing an Uncertain Future
Xconomy
From Our Advertisers
Wisconsin helps biotech company raise $20 million
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation